The therapy works by activating types of disease fighting white blood cells called natural killer (NK) cells and T-cells to create long-term immunity in the body.
Anktiva is intended for bladder cancer patients who did not respond to prior treatments. It is delivered via a catheter and prompts the patient's own immune system 'to mount a targeted attack against cancer cells.'
"The treatment offers 'a compelling alternative for patients who have exhausted conventional treatment options.'"
[
add
]
[
|
|
...
]